Page 1 of 1

Teriflunomide (Aubagio™*) significantly reduces relapses

Posted: Wed Oct 19, 2011 11:58 pm
by MSUK
Image

Sanofi and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization.

A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933